The crosstalk of cancer cells and CAFs by Notch2 and Jagged1 in the TME studied here confirms that γ-secretase inhibitors could be a promising strategy for improving anti-VEGF antibody treatment in lung cancer. This evidence concerns the gene NOTCH2 and cancer.